关注 “环球资源外贸” 官方微信，获取实时外贸资讯
Product Information
Key Specifications/ Special Features
TR20, short for TT 20mg, is a synthetic dual-incretin lyophilized peptide exclusively supplied for laboratory preclinical and cell research use. Each sealed sterile single vial contains 20 mg pure TT freeze-dried white powder, hence the product code TR20. HPLC testing verifies its purity reaches above 99.5%, free of heavy metals, pyrogens and irrelevant excipients, fully complying with research-grade peptide raw material standards.
As a dual agonist targeting GLP‑1 and GIP receptors, TR20 mimics two endogenous intestinal metabolic hormones to jointly regulate blood glucose and fat metabolism, differing from single-target GLP‑1 peptides such as sg. Before subcutaneous injection for experimental trials, TR20 dry powder must be fully reconstituted with bacteriostatic water. Undissolved lyophilized powder requires light-proof, airtight storage at -20°C for long-term stability; the diluted peptide solution retains complete biological activity for a maximum of 21 days under refrigeration (2–8°C). This product has not obtained global regulatory approval for human clinical treatment, injection or oral administration, and is limited strictly to in-vitro receptor research and animal metabolic disorder modeling experiments.
TR20 activates dual incretin pathways simultaneously to trigger glucose-dependent insulin secretion from pancreatic beta cells and suppress excessive hepatic glucagon output. It efficiently lowers fasting blood glucose and smooths postprandial blood sugar spikes, steadily reducing glycated hemoglobin levels in type 2 diabetes research models. Its dual-action design cuts the risk of hypoglycemia compared with single GLP‑1 agonists, and long-term administration alleviates chronic peripheral insulin resistance.
By delaying gastric emptying and activating satiety signals, TR20 naturally curbs calorie intake. The synergistic effect of GLP‑1 and GIP pathways accelerates lipolysis in adipose tissue, preferentially burning harmful visceral fat while preserving lean muscle mass. Research data shows TR20 delivers more stable total weight loss effects than single-target peptides, effectively lowering BMI and body fat ratio in obese animal subjects.
TR20 crosses the blood-brain barrier to act on the hypothalamic satiety center, extending post-meal fullness duration and suppressing persistent cravings for high-sugar, high-fat calorie-dense foods. It stabilizes irregular eating frequency and reduces uncontrolled overeating impulses, enabling sustainable weight management without extreme calorie restriction in research protocols.
TR20 optimizes systemic lipid profiles by lowering triglycerides and low-density lipoprotein cholesterol. It alleviates obesity-induced hypertension and obstructive sleep apnea, mitigates chronic low-grade systemic inflammation, and delivers auxiliary regulatory effects on non-alcoholic fatty liver lesions and polycystic ovary syndrome (PCOS). It also provides mild protective benefits for cardiovascular endothelial function by reducing metabolic inflammatory markers.
TR20, short for TT 20mg, is a synthetic dual-incretin lyophilized peptide exclusively supplied for laboratory preclinical and cell research use. Each sealed sterile single vial contains 20 mg pure TT freeze-dried white powder, hence the product code TR20. HPLC testing verifies its purity reaches above 99.5%, free of heavy metals, pyrogens and irrelevant excipients, fully complying with research-grade peptide raw material standards.
As a dual agonist targeting GLP‑1 and GIP receptors, TR20 mimics two endogenous intestinal metabolic hormones to jointly regulate blood glucose and fat metabolism, differing from single-target GLP‑1 peptides such as sg. Before subcutaneous injection for experimental trials, TR20 dry powder must be fully reconstituted with bacteriostatic water. Undissolved lyophilized powder requires light-proof, airtight storage at -20°C for long-term stability; the diluted peptide solution retains complete biological activity for a maximum of 21 days under refrigeration (2–8°C). This product has not obtained global regulatory approval for human clinical treatment, injection or oral administration, and is limited strictly to in-vitro receptor research and animal metabolic disorder modeling experiments.
TR20 activates dual incretin pathways simultaneously to trigger glucose-dependent insulin secretion from pancreatic beta cells and suppress excessive hepatic glucagon output. It efficiently lowers fasting blood glucose and smooths postprandial blood sugar spikes, steadily reducing glycated hemoglobin levels in type 2 diabetes research models. Its dual-action design cuts the risk of hypoglycemia compared with single GLP‑1 agonists, and long-term administration alleviates chronic peripheral insulin resistance.
By delaying gastric emptying and activating satiety signals, TR20 naturally curbs calorie intake. The synergistic effect of GLP‑1 and GIP pathways accelerates lipolysis in adipose tissue, preferentially burning harmful visceral fat while preserving lean muscle mass. Research data shows TR20 delivers more stable total weight loss effects than single-target peptides, effectively lowering BMI and body fat ratio in obese animal subjects.
TR20 crosses the blood-brain barrier to act on the hypothalamic satiety center, extending post-meal fullness duration and suppressing persistent cravings for high-sugar, high-fat calorie-dense foods. It stabilizes irregular eating frequency and reduces uncontrolled overeating impulses, enabling sustainable weight management without extreme calorie restriction in research protocols.
TR20 optimizes systemic lipid profiles by lowering triglycerides and low-density lipoprotein cholesterol. It alleviates obesity-induced hypertension and obstructive sleep apnea, mitigates chronic low-grade systemic inflammation, and delivers auxiliary regulatory effects on non-alcoholic fatty liver lesions and polycystic ovary syndrome (PCOS). It also provides mild protective benefits for cardiovascular endothelial function by reducing metabolic inflammatory markers.
,Manufacturer ,Online Seller ,Importer 